BioAtla Inc
BCAB
Company Profile
Business description
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Contact
11085 Torreyana Road
San DiegoCA92121
USAT: +1 858 558-0708
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
61
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,512.60 | 1.90 | 0.02% |
| CAC 40 | 7,873.83 | 23.73 | 0.30% |
| DAX 40 | 23,638.56 | 72.02 | 0.31% |
| Dow JONES (US) | 42,140.43 | 269.67 | -0.64% |
| FTSE 100 | 8,602.92 | 2.06 | -0.02% |
| HKSE | 23,526.16 | 417.89 | 1.81% |
| NASDAQ | 19,010.09 | 301.74 | 1.61% |
| Nikkei 225 | 38,058.81 | 124.45 | -0.33% |
| NZX 50 Index | 12,779.26 | 7.48 | -0.06% |
| S&P 500 | 5,886.55 | 42.36 | 0.72% |
| S&P/ASX 200 | 8,269.00 | 0.00 | 0.00% |
| SSE Composite Index | 3,400.92 | 26.05 | 0.77% |